F2RL1 and atopic eczema: Further developments in the PAR2 pepducin series have led to PZ-235, with blockade of PAR2 G protein signaling through the pepducin aligning with ICL3 and TM6, which is currently being explored as a potential therapeutic candidate for liver fibrosis and atopic dermatitis (90, 91).